The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk patients with metastatic hormone-naïve prostate cancer or newly-diagnosed metastatic hormone-sensitive prostate cancer.
Original Article: FDA Approves Abiraterone Plus ADT for High-Risk Prostate Cancer
NEXT ARTICLE